ETNB

89bio (ETNB)

About 89bio (ETNB)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Details

Daily high
$7.95
Daily low
$6.60
Price at open
$7.03
52 Week High
$16.63
52 Week Low
$6.43
Market cap
933.6M
Dividend yield
0.00%
Volume
4.5M
Avg. volume
1.3M
P/E ratio
-2.73

89bio News

Details

Daily high
$7.95
Daily low
$6.60
Price at open
$7.03
52 Week High
$16.63
52 Week Low
$6.43
Market cap
933.6M
Dividend yield
0.00%
Volume
4.5M
Avg. volume
1.3M
P/E ratio
-2.73